The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy

References

• . Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Obesity and overweight. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed May 24, 2010
   Google Scholar
• . Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053
   PubMed Web of Science ®Google Scholar
• . Brown CD, Higgins M, Donato KA,. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8(9):605–619
   PubMedGoogle Scholar
• . Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep. 2003;5(5):386–392
   PubMed Web of Science ®Google Scholar
• . Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications. 2010;24(6)368–374
   PubMedGoogle Scholar
• . Okosun IS, Chandra KM, Boev A,. Abdominal adiposity in U.S. adults: prevalence and trends, 1960–2000. Prev Med. 2004;39(1):197–206
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care. 2010;33( suppl 1):S3
   PubMedGoogle Scholar
• . Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200
   PubMed Web of Science ®Google Scholar
• . Hall JE, Henegar JR, Dwyer TM,. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther. 2004;11(1):41–54
   PubMedGoogle Scholar
• . Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1(1):29–35
   PubMedGoogle Scholar
• . Standards of medical care in diabetes. Diabetes Care. 2004;27( suppl 1):S15–S35
   PubMedGoogle Scholar
• . National Institutes of Health. Excerpts from the United States Renal Data System's 2000 annual data report: atlas of end-stage renal disease in the United States: incidence and prevalence of ESRD. Am J Kidney Dis. 2000;36( suppl 2):S37–S54
   Google Scholar
• . United States Renal Data System. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System Web site. http://www.usrds.org/atlas_2007.htm. Accessed May 27, 2010
   Google Scholar
• . Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1(1):8–18
   PubMedGoogle Scholar
• . Weir MR. Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. Clin J Am Soc Nephrol. 2009;4(12):2045–2050
   PubMedGoogle Scholar
• . Mauer M, Drummond K. The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes. 2002;51(5):1572–1579
   PubMedGoogle Scholar
• . de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26( suppl 4):S21–S24
   PubMed Web of Science ®Google Scholar
• . Kramer H. Obesity and chronic kidney disease. Contrib Nephrol. 2006;151:1–18
   PubMedGoogle Scholar
• . Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007;27(5):529–537
   PubMedGoogle Scholar
• . Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10
   PubMed Web of Science ®Google Scholar
• . Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hypertens. 2002;11(3):331–335
   PubMed Web of Science ®Google Scholar
• . Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15(11):2775–2791
   PubMedGoogle Scholar
• . Chen J, Muntner P, Hamm LL,. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–174
   PubMed Web of Science ®Google Scholar
• . Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol. 2008;294(4):F685–F696
   Google Scholar
• . Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28
   PubMed Web of Science ®Google Scholar
• . Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15(5):481–486
   PubMed Web of Science ®Google Scholar
• . Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardiorenal consequences, and therapeutic approaches. Med Clin North Am. 2009;93(3):733–751
   PubMedGoogle Scholar
• . Wolf G. After all those fat years: renal consequences of obesity. Nephrol Dial Transplant. 2003;18(12):2471–2474
   PubMedGoogle Scholar
• . Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des. 2007;13(21):2180–2184
   PubMedGoogle Scholar
• . Gotto AM Jr, Blackburn GL, Dailey GE 3rd,. The metabolic syndrome: a call to action. Coron Artery Dis. 2006;17(1):77–80
   PubMedGoogle Scholar
• . Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45(1):9–14
   PubMed Web of Science ®Google Scholar
• . Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44(1):12–19
   PubMedGoogle Scholar
• . Cornier MA, Dabelea D, Hernandez TL,. The metabolic syndrome. Endocr Rev. 2008;29(7):777–822
   PubMed Web of Science ®Google Scholar
• . Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–636
   PubMed Web of Science ®Google Scholar
• . Cuspidi C, Meani S, Fusi V,. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22(10):1991–1998
   PubMedGoogle Scholar
• . Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109(1):42–46
   PubMed Web of Science ®Google Scholar
• . Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16(11 pt 1):952–958
   PubMedGoogle Scholar
• . Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens. 2005;19(12):923–931
   PubMedGoogle Scholar
• . Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16(3):120–126
   PubMed Web of Science ®Google Scholar
• . Hollenberg NK. The renin-angiotensin system in the patient with diabetes: an evolution of understanding [abstract]. Am J Clin Proc. 2002;3:15–20
   Google Scholar
• . Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens. 2002;16( suppl 3):S26–S33
   PubMed Web of Science ®Google Scholar
• . Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121(8):656–663
   PubMed Web of Science ®Google Scholar
• . KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12–S154
   Web of Science ®Google Scholar
• . Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001;60(5):2041–2055
   PubMedGoogle Scholar
• . Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136(8):604–615
   PubMedGoogle Scholar
• . Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346(15):1145–1151
   PubMed Web of Science ®Google Scholar
• . Stevens LA, Schmid CH, Zhang YL,. Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant. 2010;25(2):449–457
   PubMedGoogle Scholar
• . Kraft SK, Lazaridis EN, Qiu C, Clark CM Jr, Marrero DG. Screening and treatment of diabetic nephropathy by primary care physicians. J Gen Intern Med. 1999;14(2):88–97
   PubMedGoogle Scholar
• . McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis. 1997;29(3):368–375
   PubMed Web of Science ®Google Scholar
• . Middleton RJ, Foley RN, Hegarty J,. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 2006;21(1):88–92
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Williams M, Dworkin L,. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646–661
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR,; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572
   PubMed Web of Science ®Google Scholar
• . Douglas JG. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs. 2005;5(1):1–6
   PubMedGoogle Scholar
• . Mancia G, De Backer G, Dominiczak A,; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187
   PubMed Web of Science ®Google Scholar
• . Mancia G, Laurent S, Agabiti-Rosei,; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–2158
   PubMed Web of Science ®Google Scholar
• . Rosendorff C, Black HR, Cannon CP,; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761–2788
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D,. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR,; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Parving HH. Angiotensin II Receptor Blockade in the Prevention of Diabetic Nephropathy. Am J Clin Proc. 2002;3:21–26
   Google Scholar
• . UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997
   PubMed Web of Science ®Google Scholar
• . Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25(1):134–147
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M,. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Ibsen H, Dahlof B,; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004–1010
   PubMed Web of Science ®Google Scholar
• . Ostergren J, Poulter NR, Sever PS,; ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens. 2008;26(11):2103–2111
   PubMed Web of Science ®Google Scholar
• . Ribeiro AB. Angiotensin II antagonists—therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. Curr Med Res Opin. 2006;22(1):1–16
   PubMedGoogle Scholar
• . Whelton PK, Barzilay J, Cushman WC,. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401–1409
   PubMedGoogle Scholar
• . Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672–678
   PubMed Web of Science ®Google Scholar
• . Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• . Morgan T, Anderson A, Bertram D, MacInnis RJ. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst. 2004;5(2):64–71
   PubMedGoogle Scholar
• . Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res. 2006;29(8):567–572
   PubMedGoogle Scholar
• . Weir MR. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. Postgrad Med. 2009;121(1):96–103
   PubMed Web of Science ®Google Scholar
• . Ibsen H, Olsen MH, Wachtell K,. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202
   PubMed Web of Science ®Google Scholar
• . Keane WF, Brenner BM, de Zeeuw D,. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63(4):1499–1507
   PubMed Web of Science ®Google Scholar
• . Lucchese B. Diabetes: Albuminuria and eGFR predict cardiovascular and renal risk [abstract]. Nature Reviews Nephrology. 2009;5:609
   Google Scholar
• . Ibsen H, Olsen MH, Wachtell K,. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29(3):595–600
   PubMedGoogle Scholar
• . Haller H, Viberti GC, Mimran A,. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403–408
   PubMed Web of Science ®Google Scholar
• . Croom KF, Plosker GL. Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs. 2008;68(11):1543–1569
   PubMed Web of Science ®Google Scholar
• . Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens. 2002;15(10 pt 2):123S–128S
   Google Scholar
• . Podar T, Tuomilehto J. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs. 2002;62(14):2007–2012
   PubMedGoogle Scholar
• . Ruddy MC. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens. 2002;15(5):468–471
   PubMedGoogle Scholar
• . Zanella MT, Ribeiro AB. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin Ther. 2002;24(7):1019–1034
   PubMedGoogle Scholar
• . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857–1863
   PubMed Web of Science ®Google Scholar
• . Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45(3):861–867
   PubMedGoogle Scholar
• . Mann JF, Gerstein HC, Yi QL,. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42(5):936–942
   PubMedGoogle Scholar
• . Maschio G, Alberti D, Janin G,. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939–945
   PubMed Web of Science ®Google Scholar
• . Sasso FC, Carbonara O, Persico M,. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care. 2002;25(11):1909–1913
   PubMedGoogle Scholar
• . Andersen S, Brochner-Mortensen J, Parving HH; Irbesartan in Patients With Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26(12):3296–3302
   PubMedGoogle Scholar
• . Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med. 2006;119(5 suppl 1):S40–S47
   Google Scholar
• . Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther. 2000;22(10):1213–1224
   PubMedGoogle Scholar
• . Cotter J, Oliveira P, Cunha P, Polonia J. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system. Rev Port Cardiol. 2008;27(11):1395–1404
   PubMedGoogle Scholar
• . Iino Y, Hayashi M, Kawamura T,. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27(1):21–30
   PubMedGoogle Scholar
• . Pohl MA, Blumenthal S, Cordonnier DJ,. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–3037
   PubMed Web of Science ®Google Scholar
• . Atkins RC, Briganti EM, Lewis JB,. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45(2):281–287
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Remuzzi G, Parving HH,. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320
   PubMed Web of Science ®Google Scholar
• . Eijkelkamp WB, Zhang Z, Remuzzi G,. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–1546
   PubMed Web of Science ®Google Scholar
• . Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007;24(5):486–493
   PubMedGoogle Scholar
• . Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis. 2001;37(3):477–483
   PubMedGoogle Scholar
• . ; ESCAPE Trial GroupWühl E, Trivelli A, Picca S,. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–1650
   PubMedGoogle Scholar
• . Bakris GL, Weir MR. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008;120(1):33–42
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Agarwal R, Amdahl M,. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–1551
   PubMed Web of Science ®Google Scholar
• . Kohan DE, Pritchett Y, Molitch M,. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763–772
   PubMed Web of Science ®Google Scholar
• . Mogensen CE, Neldam S, Tikkanen I,. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–1444
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M,; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Fried LF, Duckworth W, Zhang JH,. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol. 2009;4(2):361–368
   PubMedGoogle Scholar
• . Parving HH, Brenner BM, McMurray JJ,. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663–1671
   PubMed Web of Science ®Google Scholar
• . Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens. 2002;16(11):795–803
   PubMedGoogle Scholar
• . Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793–795
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Clin Ther. 1999;21(3):442–453
   PubMed Web of Science ®Google Scholar
• . Gregoire JP, Moisan J, Guibert R,. Tolerability of antihypertensive drugs in a community-based setting. Clin Ther. 2001;23(5):715–726
   PubMedGoogle Scholar
• . Koylan N, Acarturk E, Canberk A,; Turkish Irbesartan Study Group. Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study. Blood Press Suppl. 2005;1:23–31
   PubMedGoogle Scholar
• . Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 2004;27(5):335–344
   PubMedGoogle Scholar
• . Simon TA, Gelarden RT, Freitag SA, Kassler-Taub KB, Davies R. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol. 1998;82(2):179–182
   PubMed Web of Science ®Google Scholar
• . Einhorn LM, Zhan M, Hsu VD,. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–1162
   PubMed Web of Science ®Google Scholar
• . McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177–1181
   PubMed Web of Science ®Google Scholar
• . Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19(4):667–674
   PubMedGoogle Scholar
• . Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther. 2007;29(9):1803–1824
   PubMed Web of Science ®Google Scholar